Close Menu

Biogen

Far Spread

The Boston Globe reports Biogen's February conference may have been a COVID-19 super-spreader event.

The biobank will collect samples and data from Biogen employees who contracted and have recovered from COVID-19, as well as their family members and close contacts.

Closed to Clean

The Hill reports PhRMA has closed its headquarters for the week to clean following after a visitor tested positive for SAR-CoV-2.

The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.

Bringing It Back

Time magazine discusses Biogen's move to resurrect its Alzheimer's disease drug.

Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.

By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

With its recently launched BCRquest.com data analysis hub, BC Platforms has teamed with the Accelerated Cure Project for MS and Biogen.

Funded by Biogen, The University of Colorado, and The Global Down Syndrome Foundation, the project will analyze genetics and other biology in 1,000 individuals with the disorder.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.